Grants/Awards

Current Funding

The mammalian cell cycle is commonly conceived as a hard-wired pathway, but emerging work indicates that the cell cycle is much more plastic than is generally believed, with multiple routes to cell division under different conditions. The proposed project uses single-cell time-lapse microscopy and cell tracking to determine how cells are able to rapidly adapt to inhibition of a key cell-cycle regulator called CDK2. The proposed work will reveal how the cell cycle is wired for success even in the face of perturbations, which may identify ways to improve the therapeutic efficacy of targeted cell-cycle inhibitors to treat human disease.

 

A fundamental question in biology is why cells age and permanently cease to divide, a process called cellular senescence. The proposed project uses modern, single-cell technologies to characterize the onset of senescence, to determine how senescence relates to a transient state of cell-cycle withdrawal called quiescence, and to develop a molecular framework that can predict a cell鈥檚 likelihood of re-entering the cell cycle and its physiological age. Since chronological age is the major predictor for most human diseases, the proposed work could impact the treatment of multiple diseases by developing treatments to slow or even reverse human aging.

 

At Genesis we鈥檙e using the industry鈥檚 most advanced molecular AI platform to unlock tough protein targets and invent medicines with unprecedented potency and selectivity

Previous Funding

The Research Scholar Grant (RSG) supports investigator-initiated projects across the cancer research continuum. 

Independent investigators in the first 8 years (previously 6 years) of an independent research career or faculty appointment are eligible to apply. Eligibility is extended for 10 years (previously 8 years) for clinician scientists who remain active in clinical care. Applicants typically must be within 14 years of receiving a terminal (doctorate) degree and cannot have more than one R01/R01-like grant (>$100,000/year direct costs for more than 3 years) as principal investigator at the time of application.  

 

The Damon Runyon-Rachleff Innovation Award funds cancer research by exceptionally creative thinkers with 鈥渉igh-risk/high-reward鈥 ideas who lack sufficient preliminary data to obtain traditional funding. The awardees are selected through a highly competitive and rigorous process by a scientific committee comprised of leading cancer researchers who are innovators themselves. Only those scientists with a clear vision and passion for curing cancer are selected to receive the prestigious award.

Part of the High-Risk, High-Reward Research program, the award supports exceptionally creative early career investigators who propose innovative, high-impact projects in the biomedical, behavioral or social sciences within the NIH mission.

  • Single PI only
  • Must have Early Stage Investigator status (completed doctoral degree or postgraduate clinical training within last 10 years and never received a substantial NIH independent research award)
  • No preliminary data required
  • Minimum of 25% research effort
  • $1.5 million in direct costs split into two multi-year segments

PHILADELPHIA鈥擳he Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2017 class of Pew-Stewart Scholars for Cancer Research.

The five early-career scientists making up this year鈥檚 class are conducting groundbreaking research aimed at finding cures for cancer; each will receive four years of flexible funding to invest in his or her work. This is the fourth year that the Alexander and Margaret Stewart Trust has partnered with Pew to support researchers pursuing innovative work focused on advancing progress toward a cure for cancer.

The work of the 2017 class is investigating several promising avenues to slow or stop the development of cancer, including research on how to destroy leukemia cells and how cancer cells evade destruction by drug therapies.

The Research Scholar Grant (RSG) supports investigator-initiated projects across the cancer research continuum. 

Independent investigators in the first 8 years (previously 6 years) of an independent research career or faculty appointment are eligible to apply. Eligibility is extended for 10 years (previously 8 years) for clinician scientists who remain active in clinical care. Applicants typically must be within 14 years of receiving a terminal (doctorate) degree and cannot have more than one R01/R01-like grant (>$100,000/year direct costs for more than 3 years) as principal investigator at the time of application.  

鈥淭he mission of the Foundation is to support leading edge research, in the fields of chemistry and life sciences, broadly interpreted, and particularly to foster the invention of methods, instruments, and materials that open up new avenues of research and application in these sciences and related disciplines. My preference is to favor young investigators, new ideas, and a variety of projects rather than fund large, established ones of long duration.鈥

The  supports promising, early career scientific researchers, allowing them to advance their independent research and compete for major federal and private awards in the future. The applauded the Boettcher Foundation and its commitment to nurturing the state鈥檚 most promising scientific minds.

The Searle Family has maintained a strong interest in innovative biomedical research and has pursued this interest through philanthropic initiatives. The Searle Scholars Program is one of these initiatives. In his will, John G. Searle expressed the wish that certain funds be used to support ". . . research in medicine, chemistry and the biological sciences." In 1980, the family recommended the development of a program of support for young biomedical scientists. This idea evolved into the Searle Scholars Program. The program was designed to support the independent research of outstanding individuals who are in the first or second year of their first appointment at the assistant professor level, and whose current appointment is a tenure-track position. Grants are made to selected academic institutions. The program began in 1980 at the Chicago Community Trust and the first grants were made in 1981.

With the establishment of the Kimmel Scholars Program, the Sidney Kimmel Foundation changed the future of cancer research.

The Program funded the brightest young cancer researchers at the outset of their careers, creating the next generation of leaders in the fight against cancer. Annually, 15 of the nation鈥檚 most promising researchers received the $200,000 Award, selected by a world class Medical Advisory Board.

The mission of Grantome is to use data to drive discovery of new knowledge about scientific research grants. This knowledge can be applied to enhance the productivity and confer competitive advantage for researchers, institutions, and businesses that rely on grant funding. Towards this goal we have collected grant data from some of the world's largest and most prominent grant-giving organizations and assembled them into a single database.